VR Logo

Silence Therapeutics Plc American Depository Share (SLN) download report


Healthcare | Biotechnology & Pharma Research

Silence Therapeutics Plc American Depository Share (SLN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

IPO Date: 08-Sep-2020

Pres, CEO & Director: Mr. Craig A. Tooman M.B.A., MBA

Chief Financial Officer: Ms. Rhonda L. Hellums

Listing: NASDAQ: SLN

Country: United Kingdom

Headquarters: London,

Website: https://www.silence-therapeutics.com

Key Facts

Market cap: $383.41 Mln

Revenue (TTM): £14.99 Mln

Earnings (TTM): £-37.07 Mln

Cash: £59.30 Mln

Total Debt: £0.09 Mln

Insider's Holding: 9.23%

Liquidity: Low

52 Week range: $7.90 - 26.99

Shares outstanding: 29,930,400

10 Years Aggregate:

  • CFO: £-68.01 Mln
  • EBITDA: £-172.09 Mln
  • Net Profit: £-173.03 Mln

Stock Performance

Time Period Silence Therapeutics Plc American Depository Share (SLN) S&P BSE Sensex S&P Small-Cap 600
YTD-53.33-9.18-19.12
1 month12.63-4.78-8.39
3 months-41.32-9.66-14.02
1 Year-57.390.81-17.54
3 Years--10.335.95
5 Years--11.345.78
10 Years--11.749.79
As on 01-Jul-2022
Year Silence Therapeutics Plc American Depository Share (SLN) S&P Small-Cap 600 S&P BSE Sensex
20218.5925.2721.99